TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04503759

Intervention type: OTHER
Intervention: NanoBone Bone Graft Substitute
Description: Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
Study: NCT03625245

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Yogurt
Description: 125 g/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt Variety 1
Description: 125 g/day
Study: NCT03390855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts
Study: NCT03625245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt Variety 2
Description: 125 g/day
Study: NCT02598427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
Study: NCT01358357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20-80 mg flexible dose
Study: NCT03717480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClinicMACs
Description: The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants
Study: NCT00187460

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Publicly released hospital cardiac report cards
Description: Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Publicly released hospital cardiac report cards
Description: Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
Study: NCT00551629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR51 (6, 15)
Description: vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
Study: NCT03814642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg
Description: Clopidogrel 75 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Description: Clopidogrel 75 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Description: Clopidogrel 75 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Description: Esomeprazole 20 mg tablet
Study: NCT01425242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
Study: NCT02449694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Liver
Description: OCS Liver will be used to preserve the donor liver
Study: NCT01924559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard clothing
Study: NCT00757159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostim
Description: Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain
Description: Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
Study: NCT03440606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful-Compassion Art Therapy Supervision
Description: Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful-Compassion Art Therapy Supervision
Description: Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief).
Study: NCT03026764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient
Description: Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient
Description: Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
Study: NCT01924559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard clothing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard clothing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biohazard gear

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biohazard gear

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biohazard gear
Study: NCT02988791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic (BIfidobacterium, BB-12®)
Description: probiotic (Bifidobacterium, BB-12®)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00417248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
Study: NCT01924559

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Study: NCT00417248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
Study: NCT00950755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
Description: For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
Study: NCT04808167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoRIC®
Description: The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.
Study: NCT01539720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal acetate
Description: 30 mg tablet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: levonorgestrel IUS
Description: Levonorgestrel IUS, 52mg placed intrauterine
Study: NCT02772042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Study: NCT04071028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warm-water footbath
Description: All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period.
Study: NCT02561026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Frozen plasma
Description: patients randomized to receive frozen plasma transfusions
Study: NCT00656981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
Description: The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
Study: NCT03525132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry + Optic Adaptative Camera
Description: Fluxometry measure while subject is sitting in front of the optic adaptative camera
Study: NCT00462748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
Study: NCT03169582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avanafil
Description: Drug administration (Avanafil)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Drug administration (Sildenafil)
Study: NCT02046460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid, 300mg o.p.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist
Description: Vitamin K-antagonists, target INR 2.0-3.0
Study: NCT02861703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online lifestyle intervention
Description: Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
Study: NCT02722850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIVE
Description: ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIVE
Description: ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
Study: NCT03498625

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Colonoscopy
Description: Colonoscopy for CD patients in clinical remission
Study: NCT02112669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VasQ
Study: NCT03817242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanoplasty using tragal cartilage graft
Description: tympanoplasty type I is performed using tragal cartilage in arm 1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanoplasty using temporalis fascia graft
Description: tympanoplasty type I is performed using temporalis fascia in arm 2
Study: NCT01774786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
Study: NCT00462748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: atorvastatin
Description: atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: rosuvastatin
Description: rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
Study: NCT04181177

Intervention type: OTHER
Intervention: Cosmetic product
Description: Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses).
Study: NCT03429543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1000 mg/day or up to a maximal tolerated dose.
Study: NCT00656981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
Study: NCT03443206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online resources
Description: links to online mental health resources
Study: NCT01289730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 25 mg subcutaneously twice a week
Study: NCT03429543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1000 mg/day or up to a maximal tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1000 mg/day or up to a maximal tolerated dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: At least 1000 mg/day or up to a maximal tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1000 mg/day or up to a maximal tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1000 mg/day or up to a maximal tolerated dose.
Study: NCT01774786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.
Study: NCT03730688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional compartment pressure measurement
Description: Compartment pressure will be measured using the conventional compartment pressure measurement system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental compartment pressure measurement
Description: Compartment pressure will be measured using the newly-developed compartment pressure measurement system.
Study: NCT01205126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone HCl
Description: Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl CR
Description: Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
Study: NCT03429543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1000 mg/day or up to a maximal tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Basal or multiple dose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Basal or multiple dose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Basal or multiple dose injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Basal or multiple dose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Basal or multiple dose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Basal or multiple dose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Basal or multiple dose injection.
Study: NCT01774786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Study: NCT02496247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canned Herring
Description: Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
Study: NCT03255382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaderm
Description: Fumaderm tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection
Study: NCT01822080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (Visanne, BAY86-5258)
Description: 2 mg dienogest (DNG) once daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dienogest (Visanne, BAY86-5258)
Description: 2 mg dienogest (DNG) once daily by mouth